What Are the Side Effects of Meloxicam?

Meloxicam capsule, the indication is a non-steroidal anti-inflammatory drug (NSAID), which is suitable for the treatment of rheumatoid arthritis and painful osteoarthritis (arthropathy, degenerative osteoarthritis).

Meloxicam capsule, the indication is a non-steroidal anti-inflammatory drug (NSAID), which is suitable for the treatment of rheumatoid arthritis and painful osteoarthritis (arthropathy, degenerative osteoarthritis).

Drug Name

Meloxicam capsules

Drug type

Prescription drugs, medicines for medical workers' injuries

Use classification

Enoic acid

Meloxicam capsule ingredients

The main ingredient of this product is meloxicam.

Molecular formula: C ₁₄ H ₁₃ N ₃ O ₄ S ₂

Molecular weight: 315.40

Meloxicam capsule properties

This product is a capsule and the content is light yellow granules.

Meloxicam capsule indications

This product is a non-steroidal anti-inflammatory drug (NSAID), suitable for the treatment of rheumatoid arthritis and painful osteoarthritis (arthropathy, degenerative osteoarthritis).

Meloxicam capsule specifications

7.5 mg.

Meloxicam capsules dosage

1. Rheumatoid arthritis: 2 capsules / day, according to the response after treatment, the dose can be reduced to 1 capsule / day.
2. Osteoarthritis: 1 capsule / day, if needed, the dose can be increased to 2 capsules / day.
3 For patients who are likely to increase adverse reactions: start dose of 1 capsule per day.
4 When dialysis patients with severe renal failure: the dose should not exceed 1 capsule per day.
5. The appropriate dosage for children is still being determined and is currently restricted to adults.
6. The maximum recommended dosage of this product is 2 capsules / day, and it should be delivered with water or liquid.

Adverse effects of meloxicam capsules

According to foreign research data, the incidence of side effects of oral administration of this product is as follows:
1. Gastrointestinal tract: more than 1%: indigestion, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea. The frequency is between 0.1% and 1%: transient abnormal liver function indicators (such as elevated aminotransferase or bilirubin). Esophagitis, gastroduodenal ulcers, occult blood, or visible gastrointestinal bleeding. Frequency is less than 0.1%: gastrointestinal perforation, colitis.
2. Blood: more than 1%: anemia. The frequency is between 0.1% and 1%: Imbalanced blood cell counts, including white blood cell counts, leukopenia, and thrombocytopenia, and the use of potentially myelotoxic drugs, especially methotrexate, are one of the factors that cause blood cell reduction.
3 Dermatology: more than 1%: itching, rash. The frequency is between 0.1% and 1%: stomatitis, urticaria. Frequency is less than 0.1%: photosensitivity.
4 Respiratory tract: less than 0.1%: Acute asthma has been reported in individuals after aspirin or other NSAIDs, including meloxicam.
5. Central nervous system: more than 1%: slight dizziness, headache. The frequency is between 0.1% and 1%: dizziness, tinnitus, and drowsiness.
6. Cardiovascular: Frequency is more than 1%: Edema. The frequency is between 0.1% and 1%: increased blood pressure, palpitations, and flushing.
7. Urogenital system: frequency between 0.1% and 1%: abnormal renal function indicators (serum creatinine and / or serum urea increase).
8. Overdose: Because there is no known antidote, gastric emptying and supportive treatments are taken in overdose situations. Clinical trials have shown that cholestyramine can promote the excretion of meloxicam.

Meloxicam capsule contraindications

People who are allergic to this product, those with active peptic ulcer, those with severe liver dysfunction, those with non-dialysis and severe kidney dysfunction, who have symptoms of asthma, nasal polyps, angioedema or urticaria after using acetylsalicylic acid or other NSAID Patients, children under 15 years old, adolescents, and pregnant and lactating women are contraindicated.

Precautions for Meloxicam capsules

As with other NSAIDs, this product should be used in patients with a history of upper gastrointestinal tract and are using anticoagulants. If peptic ulcer or gastrointestinal bleeding occurs, this product should be discontinued.
. Patients with adverse reactions to mucous membranes and skin should pay special attention and consider stopping using this product.
.NSAID has an inhibitory effect on the prostaglandin synthesis that plays a supporting role in maintaining renal perfusion. Therefore, in patients with reduced renal blood flow and blood volume, the use of NSAID may promote significant renal decompensation. However, after NSAID is discontinued, renal function usually returns to pre-dose levels. These reactions are most likely to occur in patients who are dehydrated, patients with congestive heart failure, patients with liver cirrhosis, people with kidney disease, patients with obvious kidney disease, patients treated with diuretics, and those who have had blood caused by major surgery For patients with reduced volume, the diuretic capacity and renal function of these patients should be carefully monitored at the beginning of treatment.
There are few reports that NSAID may cause interstitial nephritis, glomerulonephritis, medullary necrosis or nephrotic syndrome. The dose of this product should not be higher than 7.5 mg for patients with advanced renal failure hemodialysis, and the dose may not be reduced for patients with moderate or mild renal manipulation (ie, patients with creatinine clarity greater than 25ml / min).
As with most other NSAIDs, occasional reports of elevated serum transaminase or other liver function parameters are mostly minor and transiently above the normal range. If this abnormality is significant or persistent, it should be discontinued This product and follow-up inspection.
For clinically stable patients with liver cirrhosis, the dose may not be reduced.
Because frail or exhausted patients have poor tolerance for side effects, they should be carefully monitored. As with other NSAIDs, care should be taken in elderly patients who may have kidney, liver and heart damage.
The effects of drugs on a person's ability to drive and use machinery have not been specifically studied, however, when adverse reactions such as dizziness and lethargy appear, it is recommended to limit these activities.

Meloxicam capsules for pregnant and lactating women

Although no teratogenic effects have been found in preclinical trials, meloxicam should not be used in pregnant and breastfeeding women.

Meloxicam capsules for children

The appropriate dose for children has not been determined, and children and adolescents younger than 15 years are prohibited.

Meloxicam capsules for elderly patients

It should be used with caution in elderly patients who may have liver, kidney and heart dysfunction.

Meloxicam capsule drug interactions

1. Large doses of other NSAIDs include salicylate: the simultaneous use of more than one NSAID may increase the likelihood of gastrointestinal ulcers and bleeding through synergistic effects.
2. Oral anticoagulants, ampicillin, and the systematic use of heparin and thrombolytic agents can increase the possibility of bleeding. If the combination is unavoidable, the effects of anticoagulants must be closely monitored.
3 Lithium: NASID has been reported to increase the plasma concentration of lithium. It is recommended to monitor plasma lithium levels when starting, adjusting and discontinuing this product.
4 Methotrexate: Similar to other NASIDs, this product will increase the blood toxicity of methotrexate. In this case, strict monitoring of blood cell count is recommended.
5. Contraception: NASID has been reported to reduce the effectiveness of IUDs.
6. Diuretics: When using NASID, patients with dehydration due to diuresis may develop acute renal insufficiency. Therefore, patients using this product and diuretics should be supplemented with sufficient water, and renal function should be monitored before treatment begins.
7. Antihypertensive drugs (such as beta receptor blockers, ACE inhibitors, vasodilators, diuretics): It has been reported that during the application of NSAID, the effect of antihypertensive drugs is reduced by inhibiting vasodilatory prostaglandins .
8. Combining cholestyramine with this product in the gastrointestinal tract can accelerate the elimination of this product.
9. Indirectly through the effect of renal prostaglandins, NSAID will increase the nephrotoxicity of cyclosporine, and renal function should be measured during combination therapy.
10 No pharmacokinetic drug-drug interactions were observed when using antacids, cimetidine, digoxin, and furosemide.
11. Interaction with oral hypoglycemic agents cannot be ruled out.

Meloxicam capsules overdose

Because there is no known antidote, gastric emptying and supportive therapy should be taken in overdose situations. Clinical trials have shown that cholestyramine can promote the excretion of meloxicam tablets.

Meloxicam capsules pharmacology and toxicology

This product is an enol non-steroidal anti-inflammatory drug (NSAID), which has strong anti-inflammatory, analgesic and antipyretic effects. It can inhibit the synthesis of prostaglandins, selectively inhibit cyclooxygenase-2 (COX-2), and is more safe than other NSAIDs.

Pharmacokinetics of Meloxicam capsules

According to foreign literature reports, meloxicam can be well absorbed by oral or anal administration. Tablets, suppositories and capsules have the same bioequivalence. Taking medication while eating has no effect on absorption. The oral drug concentration of 7.5 mg and 15 mg doses is proportional to their dosage, respectively, and can enter a stable state within 3 to 5 days. The drug concentration in patients who have been continuously treated for more than one year is similar to that of patients who first entered the stable state. In plasma, more than 99% of the drugs bind to plasma proteins. The once-daily dose causes the plasma concentration of the drug to fluctuate at a relatively small peak-to-valley range. The fluctuation range of the 7.5 mg dose is 0.4 to 1.0 mcg / ml, and the plasma concentration range of the 15 mg dose is 0.8 to 2.0 mcg / ml. Although values within this range have been observed (the lowest plasma concentration and the highest plasma concentration are in steady state, respectively). Meloxicam penetrates well into synovial fluid, with concentrations close to half that in plasma.
Meloxicam is very thoroughly metabolized, less than 5% of the daily dose of the original drug excreted from the feces, and only trace amounts of the original drug are excreted from the urine. The main metabolic pathway is the oxidation of the methyl group in the thiazolyl portion of the substance, after which this metabolite is excreted from urine or feces, about half of which is excreted from urine, and the rest is excreted from feces. The average half-life of meloxicam elimination from the body is 20 hours. Hepatic insufficiency or mild or moderate renal insufficiency had no significant effect on the pharmacokinetics of meloxicam. The average plasma clearance rate is 8ml / min, the clearance rate of the elderly is reduced, the distribution volume is small, the average is 11 liters, and the difference between individuals can reach 30% to 40%.

Meloxicam capsule storage

Keep it out of shading, keep it tightly closed, and store it out of reach of children.

Meloxicam capsule packaging

Packed in aluminum-plastic blister, 6 tablets per board; 10 tablets per board.

Expiration Date of Meloxicam Capsules

2 years ^[1]